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Abstract
Background: Graves’ is disease an autoimmune disorder of the thyroid gland caused
by circulating anti-thyroid receptor antibodies (TRAb) in the serum. TRAb mimics the
action of thyroid stimulating hormone (TSH) and stimulates the thyroid hormone
receptor (TSHR), which results in hyperthyroidism (overactive thyroid gland) and goiter.
Methimazole (MMI) is used for hyperthyroidism treatment for patients with Graves’
disease.
Methods: We have developed a model using a system of ordinary differential
equations for hyperthyroidism treatment with MMI. The model has four state variables,
namely concentration of MMI (in mg/L), concentration of free thyroxine - FT4 (in
pg/mL), and concentration of TRAb (in U/mL) and the functional size of the thyroid
gland (in mL) with thirteen parameters. With a treatment parameter, we simulate the
time-course of patients’ progression from hyperthyroidism to euthyroidism (normal
condition). We validated the model predictions with data from four patients.
Results: When there is no MMI treatment, there is a unique asymptotically stable
hyperthyroid state. After the initiation of MMI treatment, the hyperthyroid state moves
towards subclinical hyperthyroidism and then euthyroidism.
Conclusion: We can use the model to describe or test and predict patient treatment
schedules. More specifically, we can fit the model to individual patients’ data including
loading and maintenance doses and describe the mechanism,
hyperthyroidism → euthyroidism. The model can be used to predict when to
discontinue the treatment based on FT4 levels within the physiological range, which in
turn help maintain the remittance of euthyroidism and avoid relapses of
hyperthyroidism. Basically, the model can guide with decision-making on oral intake of
MMI based on FT4 levels.
Keywords: Hyperthyroidism, Methimazole, Graves’ disease, Thyroid receptor antibodies
Background
Thyroid stimulating hormone (TSH) stimulates the thyroid follicular cells by binding to
the TSH receptors (TSHR) which activates the production and secretion of thyroid hor-
mones, thyroxine (T4) and triiodothyronine (T3) into the serum. Too much T4 and T3
inhibits the production of TSH, which forms a negative feedback loop (Fig. 1). Anti-
thyroid stimulating receptor antibodies (TRAb) sometimes produced by the immune
system that circulates in the serum and mimics the action of TSH [1, 2]. As a result,
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Fig. 1 The HPT axis. A negative feedback loop of the hypothalamus-pituitary-thyroid (HPT) axis is shown in
this picture. The thyroid stimulating hormone (TSH) stimulates the thyroid gland to produce and secrete the
hormones, triiodothyrnoine (T3) and thyroxine (T4), which in turn inhibits the production of TSH. A minus
sign indicates the negative feedback
TSH goes below lower reference range and almost undetectable in the serum but TRAb
continuously stimulates the gland to produce and secrete hormones, which induces the
overactive thyroid gland (hyperthyroidism) in normal individuals [3]. This autoimmune
problem is called Graves’ disease. Graves’ disease is characterized by the loss of immuno-
tolerance to thyroid antigens and the development of TRAb due to a complex interaction
between genetic and environmental factors [4, 5]. It is classified as an organ-specific
autoimmune disease; however other organs such as the eye, the pituitary, the skin and the
joints involved in the disease process because of the presence of TSH receptors within
these organs might be targeted by TRAb [6].
The incidence rate of Graves’ disease was reported to be 20 − 30 cases per 100,000
individuals each year [7, 8]. Sex difference plays an important role in autoimmunity espe-
cially in Graves’ disease [9] and there is high risk on women aged between 40 − 50
years [1, 2]. The clinical presentation of Graves’ disease includes symptoms, physical
findings and hyperthyroidism. The symptoms may include anxiety, difficulty in sleeping,
fatigue, weight loss, palpitations and eye swelling. The physical findings may include dif-
fuse goiter, increased pulse pressure, tremor, warm moist palms and tachycardia. Graves’
hyperthyroidism can be categorized as overt or subclinical. Overt hyperthyroidism is
defined as extremely low serum concentrations of TSH and high serum concentrations
of thyroid hormones, T4 and T3 [10]. Subclinical hyperthyroidism is defined as low
serum TSH, but normal serum T4 and T3 concentrations. In the United States, the
prevalence of hyperthyroidism is approximately 1.2% (0.5% overt and 0.7% subclinical);
the most common causes include Graves’ disease, toxic multinodular goiter and toxic
adenoma [11].
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The laboratory hallmark of Graves’ hyperthyroidism is finding elevated levels of
serum free thyroid hormones, free T4 (FT4) and free T3 (FT3), associated with unde-
tectable serum TSH and positivity for serum TRAb at one point in time [12]. Approx-
imately, the normal reference range for FT4 is (7 − 18) pg/mL, FT3 is (23 − 50)
ng/L and TSH (0.4 − 4.0) mU/L respectively [13]. Graves’ hyperthyroidism is gen-
erally treated with one of the three approaches based on patients’ choice, namely
use of antithyroid drugs (thionamides) to restore euthyrodism - normal levels of thy-
roid hormones, destruction of thyroid via radioactive iodine or removal of thyroid
via surgery. Antithyroid drugs can be used as primary treatment and can be used
as pretreatment in selected patients prior to radioactive iodine therapy or prior to
surgery. So, this article focuses on antithyroid drug treatment method with Methimazole
(MMI), which results in the clinical progression of the patients from hyperthyroidism to
euthyroidism.
No perfect curative medical treatment exists for Graves’ disease; however one can
control the signs and symptoms of hyperthyroidism with the help of Methimazole
(MMI). Depending upon the severity of patients’ hyperthyroidism, the starting dose
of MMI is normally given between 10 to 60 mg per day [1], which can be contin-
ued for about 12 − 18 months until patients achieve euthyroidism. The amount of
MMI can be given as a single daily oral dose or divided doses to achieve normal-
ization of thyroid function. MMI has the benefit of once-a-day administration and a
reduced risk of major side effects [11]. After a single oral dose, the rate of absorp-
tion of MMI from the gut to serum happens rapidly and differently in hyperthyroid
patients, so the peak serum concentration of MMI reaches within 30 to 180 min
[14–16]. After the initiation of treatment, the levels of FT4 and FT3 should be mon-
itored periodically [17] and the doses should be lowered or increased in accordance
to the measured levels. In this treatment, MMI can act as an inhibitor of thyroid hor-
mone synthesis by interfering with the action of thyroid peroxidase (TPO) enzyme
in the gland. Thereby, thyroid hormone secretion gradually decreases and patients
become euthyroid over time, which is the goal of treatment (see Fig. 8). The mech-
anism of this treatment procedure can be simply described as hyperthyroidism →
euthyroidism.
Typically, higher doses of MMI is prescribed when patients are in severe hyperthy-
roidism; for example serum FT4 levels are greater than 3 times more than the upper
reference range of FT4. If higher doses are maintained for a long time period or
given when patients do not have a severe hyperthyroidism, there is a possibility for
overshooting during treatment. The mechanism of overshooting can be described as
hyperthyroidism → hypothyroidism. Similarly, lower doses of MMI are administered
sometimes during treatment because of the variability within individuals, so there is
a possibility for undershooting and that mechanism can be described as hyperthy-
roidism → subclinical hyperthyroidism. After stopping the MMI treatment, relapse of
hyperthyroidism may occur for some patients with Graves’ hyperthyroidism. Relapse
is totally independent of the type of drug and dosage administered but linked to
restoration of euthyroidism [18]. Relapse mechanism can be described as euthyroidism
→ hyperthyroidism. Some patients exhibits exacerbation which means returning to
hyperthyroidism while still on MMI treatment, as opposed to relapse (which is return
hyperthyroidism after withdrawal of MMI) [19]. In this article, we explain all of the
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possible mechanisms involved in the Methimazole treatment through a parameter from
our model.
Although the initial dose of MMI is based on FT4 levels and decided by the treating
physician, the maintenance dosages of MMI are tricky and challenging during the time
course of treatment. An appropriate maintenance dosage depends on frequent observa-
tion of the patient, which makes the treatment difficult in some sense and dependable on
patient follow-up. With the model, we can test or control FT4 levels within the physio-
logical range of (7− 18) pg/mL with appropriate maintenance dosages for the entire time
period of treatment. We can also predict or describe the relapse of hyperthyroidism after
discontinuation of MMI treatment.
Methods
Construction of a model
We present a patient-specific treatment model to describe the effect of MMI treatment
in patients with Graves’ hyperthyroidism. Basically, the model describes the clinical pro-
gression from hyperthyroidism to euthyroidism in accordance to treatment procedure.
An earlier model constructed by Langenstein et al. [20] for Graves’ hyperthyroidism did
not keep track of MMI treatment over time. However, their article was an inspiration
and provided a base for this new work. So, we build our model with the following key
assumptions and state variables.
Assumptions:
1. TRAb mimics TSH and stimulates the thyroid follicular cells to grow, produce and
secrete thyroid hormones [1].
2. After oral administration, Methimazole (MMI) absorption occurs rapidly and
almost completely from gut to blood serum and its bioavailabity is estimated to be
approximately 93% [21, 22].
3. Thyroid intakes Methimazole (MMI) from the blood serum, which in turn
inactivates the functional growth of the gland [23].
4. A portion of Methimazole (MMI) drains out from the blood serum after
intake [21, 24].
5. The functional size of thyroid gland is a hidden compartment in the
model [20, 25, 26].
6. After oral administration, the blood serum concentration of Methimazole (MMI)
exhibits a similar dynamical pattern as intrathyroidal concentration of
MMI [22, 27] (see the support for this assumption on page 449 − 450 in
the article [22] and Fig. 2).
State Variables:
• x(t) = the amount of MMI (mg) per liter of blood serum at time t.
• y(t) = the amount of FT4 (pg) per milliliter of blood serum at time t.
• z(t) = the functional size of thyroid gland (mL) or the volume of proportion of active
cells at time t.
• w(t) = the amount of TRAb (U) per milliliter of blood serum at time t.
• s(t) = the amount of MMI orally taken per day per liter of body volume (mg/L/day).
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Fig. 2 A lumped compartmental model of blood and thyroid gland. We assume Methimazole (MMI)
dynamics in the blood serum is similar to MMI dynamics in the functional thyroid gland. The release of
thyroxine (T4) depends on the stimulation of TRAb and inhibition of MMI in the functional gland
The model is given below with initial conditions.
dx
dt = s(t) −
(k1z)x
ka + x − k2x x(t0) = x0, (1)
dy
dt =
(k3z)w
kd + w − k4y y(t0) = y0, (2)
dz
dt = k5
(w
z − N
)
− k6zx z(t0) = z0, (3)
dw
dt = k7 −
k7x
kb + x − k8w w(t0) = w0 (4)
where x(t) ≥ 0, y(t) ≥ 0, z(t) > 0, w(t) ≥ 0 and the initial conditions E0 = (x0, y0, z0,w0).
In Eq. (1), the first term contains the time-dependent function s(t) , which represents
the rate of change of MMI dosing at time t. The rate of change of MMI dosing is assumed
to be zero when no MMI is taken orally. The middle term, − (k1z)xka+x , represents the uptake
rate of MMI by the thyroid gland with maximal saturation rate (k1z). We modeled the
uptake rate with Michealis-Menten kinetics as supported by the literature [28]. The last
term, −k2x, represents the excretion or elimination rate of the drug through non-specific
mechanism.
In Eq. (2), the first term, (k3z)wkd+w accounts for the secretion rate of free thyroxine, which
we modeled through the Michaelis-Menten kinetics with the maximum secretion rate as
(k3z). The second term, −k4y, represents the elimination rate of free thyroxine from the
blood.
In Eq. (3), the first term,
(w
z − N
)
, represents the growth rate of the functional thyroid
gland in the presence of TRAb in the blood wherein N indicates the maximal growth
ratio. The second term, −k6zx, represents the inactivation rate of thyroid functional size
by the MMI treatment.
In Eq. (4), the first term, k7, represents the maximum production rate of TRAb due to
autoimmune response. The middle term, − k7xkb+x , represents the inhibition rate of TRAb
due toMMI dosing.We further assume the the maximum inhibition rate is the maximum
production rate of TRAb. The maximum inhibition rate will be reached asymptotically as
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the concentration of MMI dosing increases in the blood. The last term, −k8w, represents
the natural decay rate of TRAb.
The form of this model uses the idea of the functional size of the thyroid that was devel-
oped in our first article [26]. To be more precise, the rate of change of functional size (as
opposed to thyroid size) over time was described as growth rate minus inactivation rate of
functional size. The growth rate of functional size was modeled by a fraction of TSH con-
centration to the functional size when TSH is available in the blood serum. When TSH
is not available, the growth rate decreases at physiologically standard constant rate N. By
assumption (1), we replace TSH by TRAb (see Eq. (3)). The inactivation rate of functional
size was influenced by the interaction of MMI concentration and the functional size [25].
Stability analysis
We first analyze the stability of steady state for untreated Graves’ hyperthyroidism
patients and subsequently analyze the stability of steady state for patients treated with
MMI. The following remark describes the steady state for untreated patients:
Remark 1 When s(t) = 0, we denote the hyperthyroid state as E1 = (x1, y1, z1,w1)where
x1 = 0
y1 = k3k
2
7
k4k8N (k8kd + k7)
z1 = k7k8N
w1 = k7k8
Theorem 1 When s(t) = 0 and x0 = 0, model (1)-(4) with all parameters positive
has a unique steady state E1 (hyperthyroid state) in the hyperplane x = 0, which is
asymptotically stable.
Proof By using Routh-Hurwitz criterion, we will prove that the hyperthyroid state is
locally asymptotically stable inside the hyperplane x = 0. We first assume s(t) = 0 in the
Eq. (1) and then consider the Jacobain matrix of this model, we obtain
J1 =
⎡
⎢⎢⎢⎢⎣
−(k1kaz+k2(x+ka)2)
(x+ka)2 0
−xk1
(x+ka) 0
0 −k4 wk3w+kd
zk3kd
(w+kd)2
−zk6 0 −wk5z2 − xk6 k5z−k7kb
(x+kb)2 0 0 −k8
⎤
⎥⎥⎥⎥⎦
We next evaluate the Jacobian at the hyperthyroid state, E1 = (x1, y1, z1,w1) and obtain:
J1 =
⎡
⎢⎢⎢⎢⎣
− k1k7k8Nka − k2 0 0 0
0 −k4 k3k7k8kd+k7
k3k7k8kd
N(k8kd+k7)2
− k6k7k8N 0 − k5k8N
2
k7
k5k8N
k7
− k7kb 0 0 −k8
⎤
⎥⎥⎥⎥⎦
The eigenvalues of Jacobian matrix can be found by solving the characteristic
equation det(J1 − λI) = 0, which is λ4 + a1λ3 + a2λ2 + a3λ + a4 = 0, where
a1 = k1k7k8Nka + k5k8N
2
k7 + k2 + k4 + k8
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a2 = k8Nka
(
k5k28N2+(k2+k4)k8(k5N2+k7)+k2k4k7
)+k1k7(k5k8N2+k7(k4+k8))
k7k8Nka
a3 = k8Nka((k2+k4)k5k8N
2+k2k4(k5N2+k7))+k1k7(k5k8N2+k4(k5N2+k7))
k7Nka
a4 = k4k5k8N(k2k8Nka+k1k7)k7ka
Since all parameters from the model are positive, a1 > 0, a3 > 0, a4 > 0. We will now
verify the criteria: a23 + a21a4 − a1a2a3 < 0 to ensure the asymptotically stability of the
hyperthyroid state inside the hyperplane x = 0 [29].
a23 + a21a4 − a1a2a3 = −
f
k37k28N3k3a
< 0
where
f = (k4 + k8)
(
k5N2 + k7
) (
k5k8N2 + k4k7
)
((k2 + k4) k8Nka + k1k7)
(k8 (k2 + k8)Nka + k1k7)
(
k8Nka
(
k5k8N2 + k2k7
) + k1k27)
> 0
This completes the proof.
Remark 2 We denote the euthyroid steady state as E2 = (x2, y2, z2,w2). The analyti-
cal description of this state is not possible. So, we present the qualitative analysis of the
existence of the euthyroid state and its stability.
Theorem 2 When s(t) = c > 0 (treatment parameter) and x0 > 0, model (1)-(4) with
all parameters positive has a unique euthyroid state E2 = (x2, y2, z2,w2) in the positive
orthant. Moreover, z2, y2, w2 are all decreasing functions of c if
c < k1z2 + k2ka + 2k2x2 − k1x2
[ k5k7kb
k8(kb + x2)2 + kbz
2
2
] 1
(Nk5 + 2k6x2z2)
Proof We first assume s(t) = c > 0 in the Eq. (1) where c is a positive real number or
treatment parameter. To confirm the existence of euthyroid state in the positive orthant,
we set the right hand side of (1)-(4) to zero;
c − (k1z)xka + x − k2x = 0 (5)
(k3z)w
kd + w − k4y = 0 (6)
k5
(w
z − N
)
− k6zx = 0 (7)
k7 − k7xkb + x − k8w = 0 (8)
For euthyroid state E2 = (x2, y2, z2,w2), we have an equation from (5)
cka + (c − k1z2 − k2ka)x2 − k2x22 = 0 (9)
Equation (9) is the quadratic equation for x2, which has a positive root and a negative root
for (c − k1z2 − k2ka) < 0 or (> 0) with all parameters are positive. By Descarte’s Rule of
Signs, we see there is a sign change for (9) so there exists a root x2 in the positive orthant.
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From (8), we have a single equation
w2 = k7kbk8(kb + x2) (10)
Notice that if x2 lies in the positive orthant, then w2 lies in the positive orthant for all
positive parameters. From (7), we have a quadratic equation for z2
k6z22x2 + Nk5z2 − k5w2 = 0 (11)
By Descarte’s Rule of Signs, we see there is a sign change for (11) for x2 > 0 and w2 > 0
so there exists a root z2 in the positive orthant. From (6), we have an equation
y2 = k3z2w2k4(kd + w2) (12)
which also lies in the positive orthant for z2 > 0 and w2 > 0. Therefore, there exists a
unique euthyroid state E2 = (x2, y2, z2,w2) in the positive orthant when c > 0.
Differentiating implicitly both sides of (9), (10) ,(11) and (12) with respect to c, we obtain
the following partial differential equations:
∂x2
∂c =
ka +
(
1 − k1 ∂z2∂c
)
x2
k1z2 + k2ka + 2k2x2 − c (13)
∂w2
∂c =
−k7kb
k8(kb + x2)2
∂x2
∂c (14)
∂z2
∂c =
−∂x2
∂c
[ k5k7kb
k8(kb + x2)2 + kbz
2
2
] 1
(Nk5 + 2k6x2z2) (15)
∂y2
∂c =
k4kdk3z2 ∂w2∂c +
(
k4kdk3w2 + k4k3w22
)
∂z2
∂c
k4(kd + w2)2 (16)
Substituting (15) into (13), we obtain an equation;
∂x2
∂c =
ka + x2
k1z2 + k2ka + 2k2x2 − c − k1x2
[
k5k7kb
k8(kb+x2)2 + kbz
2
2
]
1
(Nk5+2k6x2z2)
(17)
Suppose the denominator of (17) is positive, we have ∂x2
∂c greater than zero, then
∂w2
∂c ,
∂z2
∂c
and ∂y2
∂c are all negative, which implies w2, z2, y2 are all decreasing functions of c.
Theorem 3 The euthyroid state E2 = (x2, y2, z2,w2) is locally asymptotically stable in
(1)-(4) when s(t) = c > 0 and w = Nz.
Proof Let x = x − x2, y = y − y2, z = z − z2 and w = w − w2. We define a Lyapunov
function V : 4 →  by the equation
V (x, y, z,w) = x
2
2 + xw +
w2
2 (18)
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Without loss of generality, we see the system (1)-(4) becomes (19)-(22) in the new
coordinates;
dx
dt = −
xz + xz2 + x2z
f1 + w − k2x (19)
dy
dt =
k3 (zw + z2w + w2z)
f2 + w − k4y (20)
dz
dt = k5
(w + w2
z + z2 − N
)
− k6zw − k6z2w − k6zw2 (21)
dw
dt = −
k7(x2 + x)
f3 + x − k8w (22)
For the system (19)-(22), (0, 0, 0, 0) is an equilibrium point if w = Nz. Moreover
V (0, 0, 0, 0) = 0 if (x, y, z,w) = 0, V (x, y, z,w) > 0 for all (x, y, z,w) in the positive orthant
and
dV
dt =
∂V
∂x
dx
dt +
∂V
∂y
dy
dt +
∂V
∂z
dz
dt +
∂V
∂w
dw
dt
= −(x + w)
(xz + xz2 + x2z
f1 + w + k2x +
k7(x2 + x)
f3 + x + k8w
)
< 0
Therefore, the origin is locally asymptotically stable for (19)-(22) and thus euthyroid state
is locally asymptotically stable for (1)-(4). This completes the proof.
Numerical simulations
Data
We have 90 Graves’ hyperthyroidism patients data in which we have information for
steady state levels of free thyroxine (FT4), free triiodothyronine (FT3), thyroid receptor
stimulating antibodies (TRAb), thyroid peroxidase antibodies (TPOAb), thyroglobulin
antibodies (TgAb), Methimazole (MMI) loading and maintenance dosage levels and age
(Additional file 1). Serum TRAb is a bio-marker for Graves’ disease, however it is not a
criterion for the dose of antithyroid drugs [11]. So, antithyroid drug (MMI) is prescribed
based on solely FT4 and FT3 levels. When data was collected, FT4 and FT3 measured in
SI units (pmol/L) that we converted FT4 to the conventional unit (in terms of pg/mL) by
using the factor 0.7769 and converted FT3 to the conventional unit (in terms of ng/L) by
using the factor 0.651 for our purposes [30]. Since FT4 data was collected from different
labs across Sicily, Itlay, the normal reference range adopted by these labs was different. So,
we have center the FT4 data for commonly used clinical reference range (7−18) pg/mL by
using the formula y = (18−7)∗(x−LFT4)
(UFT4−LFT4) + 7, where x is a actual measurement of FT4 value
(in pg/mL), LFT4 and UFT4 are lower and upper reference range values of FT4 used in
the labs (in pg/mL). The same idea for the formula was used in our previous articles [26,
31]. For some patients in our data, TRAb was not measured in the first visit due to high
levels of FT4 and that indicated the 1st evidence of hyperthyroidism. Just note that TSH
were undetectable for many of our patients at the first clinical visit.
Based on the levels of FT4, MMI loading dosage started with six, four, three or two
tablets per day for one or two months. Each tablet consists of 5 mg of MMI. After ini-
tial treatment, the loading dosage tablets were decreased for almost all patients by one
Pandiyan et al. Theoretical Biology andMedical Modelling  (2018) 15:1 Page 10 of 25
tablet stepwise for every month. After loading dosage or during follow up, the mainte-
nance dosage would be started when patients FT4 levels were controlled within normal
range. Typically, one or half tablet per day was prescribed as the maintenance dosage and
the entire MMI therapy lasts for about 12 to 24 months. Once patients achieved euthy-
roidism, MMI therapy would be stopped and patients were all asked to check their FT4
levels periodically to avoid relapses of hyperthyroidism. After stopping therapy, relapses
may occur for some patients. If relapses occur, then MMI therapy would be administered
again. In our data bank, we have some patients went through two courses of MMI treat-
ment. Antibodies TRAb, TPOAb and TgAb are not measured routinely during therapy, as
the healthcare system would not reimburse patients. A summary statistics of FT3, FT4,
TRAb, TPOAb and TGAb for the 1st evidence of hyperthyroidism can be found in the
Table 1.
Initial conditions
We can calculate the initial concentration of the Methimazole (MMI) in the blood serum
as follows
x0 = Loading doseVolume of distribution in blood serum
Loading dose information can be obtained from data and can assume the volume of dis-
tribution in blood serum approximately 3 L. The initial state of the FT4 (y0) and TRAb
(w0) can be measured at the steady state levels for each patient so it can be found from the
patient’s data. The initial state of the functional size of the thyroid glandmay be calculated
via the equilibrium argument from Eq. (1), if the parameters k1, ka and dose function s(t)
are known; that is,
z0 = (s(t) − k2x0)(ka + x0)k1x0
We can calculate s(t) and k2 from MMI dosing information but parameters k1 and ka are
difficult to estimate due to high variability in patients’ thyroid gland MMI uptake and
MMI distribution in blood and body volume. So, we consider the functional size as an
hidden compartment and assume z0 = 30 mL for hyperthyroidism patients. With this
assumption, we estimate parameter values k1 and ka in next section. Therefore, our initial
conditions for numerical simulation is of the form E0 = (x0, y0, 30,w0).
Parameter estimates
With twelve positive parameters and a dose (rate) function s(t) in this model, we have
to determine the numerical values for these parameters and a function via patients data,
thyroid literature and equilibrium argument of hyperthyroidism state. A summary of the
Table 1 Summary statistics of FT3, FT4, TRAb, TPOAb and TGAb for 1st clinical visit of 90 patients
FT3: FT4: TRAb: TPOAb: TGAb:
(23 - 50) ng/L (7 - 18) pg/mL (0 - 1) U/mL (<100) U/mL (<100) U/mL
Mean 77.5 32.6 16.05 793.5 795.2
Median 70.9 31.2 11.4 263.5 138.5
Mean variability 77.5 ± 37.5 32.6 ± 11.3 16.05 ± 22.5 793.5 ± 1822.2 795.2 ± 3760
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parameter estimates can be found in Table 2. In Eq. (1), we first calculate the dose function
s(t) = c based on the loading dosage schedule information and bio-availability of MMI
(f = 93%). Typically, dosing schedule of a patient is obtained from the data. Suppose the
loading dosing schedule is 30 mg/day for 45 days for the average man with body volume
59.71 L, then
s(t) =
{ 0.93×30 mg/day×45 days
59.71L = 21.027mg/L if 0 ≤ t ≤ 45
0 Otherwise
The maximum uptake rate of MMI is obtained from the information in literature [28].
Huang G et. al observed that as MMI dosage varies from 5 to 15 mg/day, intrathy-
roid levels of MMI increased with increasing dose, but without significant increase
when 15 mg/day. Their results indicate the maximum saturation rate of intrathyroidal
concentration of MMI 15 mg/day. Suppose the normal functional size of the gland in
hyperthyroidism is z0 = 30 mL, then we can estimate k1 = 1530∗59.71 = 8.374 ×
10−3 mg/mL*L day. Next, the literature says MMI excretion happens in about 12 of the
day for the maximum amount of 15 mg/day. With this information, we determined the
value of ka = 0.358068 mg/L through simulations. The rate of elimination of MMI
through non-specific mechanism is assumed to be exponential which can be calculated
as k2 = ln(2)5 h = 3.32711/day.
In Eq. (2), we first estimate kd through fmincon optimization procedure in Matlab
R2015a with lower bound 0.05 and upper bound 0.1. Next, we calculate k3 via the equi-
librium argument with initial steady state, E0 = (x0, y0, z0,w0). Note when x0 = 0, the
initial steady state represent hyperthyroidism state. From the data, we have information
for hyperthyroidism state for each patient from their 1st visit, so the initial concentration
of TRAb (w0), initial concentration of FT4 (y0) and the functional size of thyroid gland
(z0) yields;
dy
dt = 0 =
k3z0w0
(kd + w0) − k4y0
k3 = k4y0(kd + w0)z0w0
Table 2 Parameter Estimates, Description, Units and Source
Parameter Description Value Source Units
k1 Relative maximum uptake rate of MMI 8.374 × 10−3 Literature [28] mg/(mL ∗ Lday)
k2 Elimination rate of MMI 3.3271 Estimated 1/day
ka Michealis-Menten constant for half maximal
uptake rate of MMI
0.358068 Simulation mg/L
k3 Relative maximum secretion rate of FT4 0.119 Calculation pg/(mL2day)
kd Michealis-Menten constant for half maximal
secretion rate of FT4
0.05 Simulation U/mL
k4 Elimination rate of FT4 0.099021 Estimated 1/day
k5 Relative growth rate of the functional size of
thyroid gland
1 × 106 Simulation mL3/(U ∗ day)
N Maximal growth ratio 0.833 Calculation U/(mL2)
k6 Thyroid inactivation rate constant 0.001 Simulation mL/mg ∗ day
k7 Maximal production rate of TRAb 0.875 Calculation U/(mL ∗ day)
kb Inhibition rate of TRAb 1.5 Simulation mg/L
k8 Elimination rate of TRAb 0.035 Estimated 1/day
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The parameter k4 is the excretion rate of FT4 which assumed to be exponential due to a
non-specific mechanism so it can be calculated as k4 = ln(2)7days = 0.099021 1/day.
In Eq. (3), we determine the value of N from the initial concentration of TRAb (w0) and
the functional size of the thyroid gland (z0) at the hyperthyroid state or from the patients
data. Again, the equilibrium argument was used to estimate the parameter N = w0z0 when
the MMI treatment was not given. The parameters k5 and k6 were assumed to be one as
found through the simulation.
In Eq. (4), we determine the maximal production rate of TRAb at the hyperthyroid
state of patient. More precisely, the parameter estimate of k7 = k8w0 in the absence of
MMI treatment. The parameter k8 was the death rate of TRAb, which we assume to be
exponential in the model and that was calculated as k8 = ln(2)20 days = 0.035 1/day. The
parameter kb was the half-maximal inhibition concentration of TRAb (Michalies-Menten
constant) that can be estimated with fmincon procedure with lower bound 3 and upper
bound 12.
Simulation of the model
We will now numerically simulate our model for a finite time period based on the
MMI treatment. Consider a hypothetical hyperthyroid patient whose initial state is
E0 = (0, 36, 30, 25) and parameter values are taken from Table 2. Without MMI treat-
ment (i.e., s(t) = 0), Fig. 3 shows the patient steady state levels remains the same for
10 days. We will now discuss various treatment scenarios with the assumption of body
volume of this patient 59.71L. Suppose when effective dose of 30 mg of MMI is given
for 1 day, the initial state becomes E0 = (10, 36, 30, 25) and Fig. 4 shows the patient
has almost no change in their dynamics. Just recall we assumed one single large MMI
dose is taken everyday, which is absorbed immediately and completely by the patient’s
body. So, the initial state was the last point in the previous run or simulation. Suppose
the effective loading dosage of 30 mg/day are administered for 25 days, Fig. 5 shows the
patient’s FT4 levels decreased from 36 pg/mL but ended up in the subclinical hyperthy-
roidism (Undershooting). Suppose the effective loading dosage schedule is maintained
as 30 mg/day for 90 days, Fig. 6 shows the patient’s FT4 levels decreased below the
lower reference range of FT4 which in turn resulted in hypothyroidism (overshooting).
So, in order to avoid overshooting, the loading dosage should be administered less than
90 days.
Suppose the loading dose is given 30 mg/day for 45 days, Fig. 7 shows patient’s FT4 lev-
els decreased closer to the upper normal reference limit. Suppose the loading dose is given
30 mg/day for 60 days, Fig. 8 shows patient’s FT4 levels decreased to the normal refer-
ence range. Next, our goal is to maintain the FT4 levels within the reference range, so the
loading dose of MMI is reduced to 10 mg/day and given for 120 days. Figure 9 shows the
effect of MMI loading and maintenance dosage schedule for 180 days. After 180 days of
treatment, patient’s FT4 levels are closer to lower normal reference limit. So, MMI dosage
levels further lowered to 5 mg/day for 20 days which in turn increased FT4 levels within
the normal reference range and then the regular maintenance dose of 10 mg/day is given
for another 120 days (see Fig. 10). This cycle of treatment is repeated again for another
140 days (see Fig. 11) and the patient’s FT4 levels are completely controlled within the ref-
erence range. Relapse of hyperthyroidism is a tricky mechanism after stopping the MMI
treatment, which may or may not occur for patients. If relapse occurs, then the model
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Fig. 3 With E0 = (0, 36, 30, 25) and s(t) = 0 mg/L/day, the untreated patient steady state levels remains
same for 10 days
Fig. 4 With E0 = (10, 36, 30, 25), suppose the loading dosage = 30 mg is given for 1 day which results in
almost no change in patient’s FT4 steady state levels. The dotted lines are shown to indicate the lower and
upper reference limit of FT4
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Fig. 5 With E0 = (10, 36, 30, 25), suppose the loading dosage = 30 mg/day is given for 25 days which results
in subclinical hyperthyroidism (Undershooting)
can explain this mechanism. Suppose if we assume the treatment of patient is stopped
after one loading andmaintenance dosing schedule (that is after 180 days), see Fig. 12 that
shows the relapse of hyperthyroidism.
Model validation
In this section, we will validate our model, so our task now is to simulate the model
numerically for finite time and compare it with time course data. For validation purposes,
we will arbitrarily choose four patients data from our data bank and calculate patient-
specific and medication parameters using their measurement data, which in turn will be
Fig. 6 With E0 = (10, 36, 30, 25), suppose the loading dosage = 30 mg/day is given for 90 days which results
in hypothyroidism (overshooting)
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Fig. 7 With E0 = (10, 36, 30, 25), suppose the loading dosage = 30 mg/day is given for 40 days which results
in patient’s FT4 levels close to the upper normal reference limit
fed into the model for finite time simulation. See Table 3 for these four patients param-
eter values. The simulation of the model will be done in accordance with patient’s MMI
loading and maintenance dosing schedule. The dosing schedule of these patients will
also help us calculate the dosing rate function s(t) = c. So, we fix all parameters during
simulation except the dosing rate function c. To analyze the simulation output, we have
estimated a root mean square error reference interval for FT4 and TRAb from patients’
Fig. 8 With E0 = (10, 36, 30, 25), suppose the loading dosage = 30 mg/day is given for 60 days which results
in patient’s FT4 levels within the normal reference range
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Fig. 9 With E0 = (10, 36, 30, 25) and the loading dosage = 30 mg/day for 60 days results in patient’s FT4
levels within normal reference limit. After that, the maintenance dosage = 10 mg/day is given for 120 days in
order to control FT4 levels within normal reference range
Fig. 10 After the oral administration of loading dosage = 30 mg/day (for 60 days) and maintenance dosage
=10 mg/day (for 120 days), patient’s FT4 levels reaches closer to lower normal reference limit, so MMI dosage
is lowered to 5 mg/day for 20 days. This in turn increased the levels of FT4 and then maintenance dosage
continued for another 120 days
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Fig. 11 When patient’s FT4 levels reaches again closer to the lower normal reference limit, the maintenance
dosage is lowered to 5 mg/day from 10 mg/day and then the regular maintenance dosage continued for up
to 120 days in order to maintain FT4 levels within normal reference limit
data. To estimate the reference interval, we eliminated patients with missing TRAb data.
In other words, we considered only patients with at least three TRAb values at different
time-points in the data set (27 patients). So, we have obtained a non-normalized refer-
ence interval (0.88, 36.40) for FT4 and (0.17, 15.73) for TRAb respectively (Additional
file 2).
Fig. 12 After the withdrawal of MMI treatment, the relapse of hyperthyroidism had occurred for the
hypothetical patient
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Table 3 Individual patient parameter values
Parameter Patient# 20 Patient# 31 Patient# 55 Patient# 70
k1 8.374 × 10−3 8.374 × 10−3 8.374 × 10−3 8.374 × 10−3
k2 3.3271 3.3271 3.3271 3.3271
ka 0.358068 0.358068 0.358068 0.358068
k3 0.085 0.08975 0.08992 0.11784
kd 0.067 0.07 0.081 0.075
k4 0.099021 0.099021 0.099021 0.099021
k5 1 × 106 1 × 106 1 × 106 1 × 106
N 0.250 0.058 0.207 0.293
k6 0.001 0.001 0.001 0.001
k7 0.26 0.061 0.22 0.308
kb 4.95 11.8 4.09 3.15
k8 0.035 0.035 0.035 0.035
Note: The values of k3, kd , N, k7 and kb varies among patients
Wewill first explain patient #20 time course data and then simulate the model in accor-
dance with MMI treatment. In November 2010, this patient was diagnosed with Graves’
hyperthyroidism. At the first clinical visit, patient’s FT4 and TRAb levels were 25.63
pg/mL and 7.5 U/mL respectively with respect to normal reference ranges of FT4, (7 - 18)
pg/mL and TRAb, (0 - 1) U/mL. At this visit, this patient was put underMMI treatment. A
loading dosage was started with 6 tablets/day and asked to decrease tablets consumption
by one stepwise every month. So, patient #20 took 6 tablets/day (i.e., 30 mg/day) for first
month, 5 tablets/day (i.e., 25 mg/day) for secondmonth and 4 tablets/day (i.e., 20 mg/day)
for third month. After third month, patient followed up for check-up and the dosage was
lowered to 2 tablets/day (i.e., 10 mg/day) for next three months because FT4 levels were
17.7 pg/mL (close to upper normal reference limit) and TRAb levels were not measured
at this visit. After six months, patient visited the clinic and FT4 levels were measured 13.8
pg/mL (but not TRAb) and the dosage was further lowered to 1 tablet/day and prescribed
for another six months. Now, after twelve months or 1 year, patient’s FT4 and TRAb was
13.14 pg/mL and 0.7 U/mL so the dosage level continued with same amount 1 tablet/day
for another six months. Finally, after 1 year and six months, FT4 and TRAb was 12.46
pg/mL and 0.6 U/mL; therefore MMI dosage was stopped.
Next, we simulate the model for patient #20 based on MMI loading and maintenance
dosage information. Depending upon the consumption of amount of MMI, we calculated
the parameter value c for each time period and run the model. For the 1st time period
(1 month), the value of c = 14.02 and the initial value x0 = 30/3 = 10 mg/L, y0 = 25.63
pg/mL, z0 = 30 mL and w0 = 7.5 U/mL. For the 2nd time period (1 month), the value of
c = 12.07 and the initial value was the last point in the previous run or simulation. For the
3rd time period (1 month), the value of c = 9.6534 and the initial value was the last point
in the previous run. For the 4th time period (3 months), the value of c = 13.8663 and the
initial value was the last point in the previous simulation. For the 5th and 6th time period
(i.e., 1 year), the value of c = 14.173 and the initial value was the last point in the previous
run. The other parameter values were all fixed in the simulation (see Table 3 and Fig. 13).
To find the accuracy of model fit to data, we calculate a measure of prediction; the root
mean square error. It is computed from the square root of the average sum of squared
residuals of the fit. For patient #20 data, we found the root mean square error for the fit
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Fig. 13 A course of MMI treatment is given for patient #20. Both FT4 and TRAb data is plotted with the
simulated solutions. The root mean square error for the fit of FT4 and TRAb data is 0.889 and 2.388
respectively. Blue dots indicate FT4 levels while magenta dots indicate TRAb levels in the figure
of FT4 and TRAb data is 0.889 and 2.388 respectively. It is probably a good measure of
accuracy for the available time course data, so generating patient treatment schedule may
be reliable for patient #20.
As before, we first explain patient #31 time course data and then proceed with model
validation. At the first visit, this patient’s FT4 and TRAb levels were 26.43 pg/mL and 1.74
U/mL respectively, which indicates Graves’ hyperthyroidism in accordance with normal
reference range. So, this patient was put under MMI treatment. The treatment initiated
with loading dose of 4 tablets/day for 1st month, lowered stepwise to 1 tablet/day. That is,
3 tablets/day for 2nd month, 2 tablets/day for 3rd month and 1 tablet/day for 4th month.
After 4 months taking MMI, patient’s follow-up revealed FT4 levels were 20 pg/mL and
TRAb was not measured at that time. The treatment was continued with 2 tablets/day for
1 month and then 1 tablet/day for 23 months. In a subsequent follow-up, MMI treatment
was discontinued because FT4 and TRAb levels were 11.5 pg/mL and 0.45 U/mL respec-
tively. Patient #31 followed-up for check up after 2 years of no treatment, FT4 and TRAb
levels were 11.36 pg/mL and 0.43 U/mL normal.
Next, we simulate the model for patient #31 based on MMI loading and maintenance
dosage information. Based on dosages, we calculate the value of c. For the 1st time period
(i.e., 1 month), the value of c = 9.3456 and the initial value x0 = 20/3 = 6.67 mg/L,
y0 = 26.43 pg/mL, z0 = 30 mL and w0 = 1.74 U/mL. For the 2nd time period (i.e.,
1 month), the value of c = 7.01 and the initial value was the last point in the previous
run. For the 3rd time period (i.e., 1 month), the value of c = 4.6726 and the initial value
was the last point in the previous run. For the 4th time period (i.e., 1 month), the value
of c = 2.3363 and the initial value was the last point in the previous simulation. For the
5th time period (i.e., 1 month), the value of c = 4.6726 and the initial value was the
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last point in the previous simulation. For the 6th time period (i.e., 23 months), the value
of c = 53.7345 and the initial value was the last point in the previous run. The total
treatment time period was about 840 days (see Fig. 14 and Table 3). There is a lack of data
for patient #31, however we fit the model to the available data and provide a measure of
prediction; the root mean square error (RMSE). The RMSE for the fit of FT4 and TRAb
data is 1.9892 and 0.2303 respectively. The smaller RMSE for TRAb and slightly larger
RMSE for FT4 indicates a reasonable amount of accuracy so generating patient treatment
schedule may be reliable for patient #31.
As before, we first explain patient #70 time course data and then validate the model.
At the first clinical visit, this patient’s FT4 and TRAb levels were 35.04 pg/mL and 8.8
U/mL respectively, which indicates Graves’ hyperthyroidism in accordance with nor-
mal reference range. So, this patient was put under MMI treatment at this visit. MMI
dosage was prescribed as 6 tablets/day for first month, 5 tablets/day for second month, 4
tablets/day for third month, 3 tablets/day for fourth month, 2 tablets/day for fifth month
and 1 tablet/day from sixth month to tenth month (that is to say four months of mainte-
nance dosage). After tenthmonth, patient’s FT4 and TRAb were 9.3 pg/mL and 1.3 U/mL,
so MMI treatment was continued with 1 tablet/day for another seven months. So, after
seventeen months, patient followed up for check-up and now FT4 and TRAb were 8.97
pg/mL and 1.4 U/mL. Since FT4 measurement was closer to the lower reference range,
MMI treatment was stopped for six months after this visit but asked to follow up on the
thyroid status. Then, after six months, patient’s FT4 and TRAb levels were 31.2 pg/mL
and 4.7 U/mL respectively so relapse occurred. A second course ofMMI treatment started
again with 4 tablets/day for 1 month, 2 tablets/day for three months and then 1 tablet/day
for three months. In the follow-up of after seven months, patient’s FT4 and TRAb levels
were 9.87 pg/mL and 0.9 U/mL respectively. MMI treatment continued with lower dosage
1 tablet/day for another six months and then patient FT4 levels remained as 9.87 pg/mL
but TRAb levels decreased to 0.3 U/mL. Finally, treatment was stopped.
We now simulate the model for patient #70 based on MMI loading and maintenance
dosage information. For the 1st time period (i.e., 1 month), the value of c = 14.02 and the
Fig. 14 A course of MMI treatment is given for patient #31. Both FT4 and TRAb data is plotted with the
simulated solutions. The root mean square error for the fit of FT4 and TRAb data is 1.9892 and 0.2303
respectively. Blue dots indicate FT4 levels while magenta dots indicate TRAb levels in the figure
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initial value x0 = 30/3 = 10 mg/L, y0 = 35.04 pg/mL, z0 = 30 mL and w0 = 8.8 U/mL.
For the 2nd time period (i.e., 1 month), the value of c = 11.6817 and the initial value was
the last point in the previous run or simulation. For the 3rd time period (i.e., 1 month),
the value of c = 9.3456 and the initial value was the last point in the previous run. For
the 4th time period (i.e., 1 month), the value of c = 7.0089 and the initial value was the
last point in the previous simulation. For the 5th time period (i.e., 1 month), the value of
c = 4.6726 and the initial value was the last point in the previous simulation. For the 6th
time period (i.e., 11 months), the value of c = 25.6996 and the initial value was the last
point in the previous run. After 17 months, treatment was stopped so we set the value
of c = 0.001 and run the model for six months. Relapse of hyperthyroidism occurred so
the second course of MMI treatment started. For the 1st time period(i.e., 1 month), the
2nd time period (i.e., 3 months) and 3rd time period (i.e.,10 months), the values of c are
9.3456, 14.02 and 23.3625 respectively. All parameter values are fixed in the simulation
except c (see Table 3 and Fig. 15). To determine the accuracy of model fit to data, we
calculated the root mean square error (RMSE) for the model fit of FT4 and TRAb data,
which is 1.7006 and 1.5084 respectively. The smaller RMSE indicates a reasonable amount
of accuracy so generating patient treatment schedule may be reliable for patient #70.
As before, we first explain patient #55 time course data and proceed to model vali-
dation. At the first clinical visit, this patient’s FT4 and TRAb levels were 27.01 pg/mL
and 6.22 U/mL respectively, which indicates Graves’ hyperthyroidism in accordance with
normal reference range. So, this patient was put under MMI treatment at this visit. MMI
dosage was prescribed as 3 tablets/day for first month, 2 tablets/day for second month
and 1 tablets/day for third month. After third month during follow-up, patient’s FT4 lev-
els measured as 10.03 pg/mL and TRAb not measured, so MMI treatment was continued
with 1 tablet/day for another six months. After nine months, patient’s FT4 and TRAb lev-
els were 8.99 pg/mL and 1.17 U/mL respectively. Since FT4 measurement was closer to
the low normal reference limit, MMI treatment was stopped. During follow-up after 23
months of no treatment, patient’s FT4 and TRAb levels were 40.28 pg/mL and 2.46 U/mL
respectively and therefore relapse occurred. A second course of MMI treatment started
Fig. 15 Two courses of MMI treatment is given for patient #70. Both FT4 and TRAb data is plotted with the
simulated solutions. The root mean square error for the fit of FT4 and TRAb data is 1.7006 and 1.5084
respectively. Blue dots indicate FT4 levels while magenta dots indicate TRAb levels in the figure
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with loading dose 4 tablets/day for first month, 3 tablets/day for second month and 2
tablets/day for third month. After third month during follow-up, patient’s FT4 levels were
12.41 pg/mL and TRAb levels not measured. Treatment was continued with lower dosage
1 tablet/day for another five months and then FT4 levels were measured as 10.79 pg/mL
and TRAb not measured. Treatment continued again for another 11 months with lower
dosage of 1 tablet/day. In a subsequent follow-up, patient’s FT4 levels and TRAb levels
were 11.36 pg/mL and 0.7 U/mL respectively.
Next, we simulate the model for patient #55 based on the above dosage information.
For the 1st time period (i.e., 1 month), the value of c = 7.01 and the initial value x0 =
20/3 = 6.7 mg/L, y0 = 27.01 pg/mL, z0 = 30 mL and w0 = 6.2 U/mL. For the 2nd
time period (i.e., 1 month), the value of c = 4.6726 and the initial value was the last point
in the previous run or simulation. For the 3rd time period (i.e., 1 month), the value of
c = 2.3363 and the initial value was the last point in the previous run. For the 4th time
period (i.e., 10 months), the value of c = 23.3625 and the initial value was the last point
in the previous simulation. For the 5th time period (i.e., no treatment for 23 months),
the value of c = 0.001 and the initial value was the last point in the previous simulation.
Relapse of hyperthyroidism occurred so the second course of MMI treatment started.
For the 6th time period (i.e., 1 month of loading dose), the value of c = 9.3456 and the
initial value was the last point in the previous run. For the 7th time period (i.e., 1 month),
the value of c = 7.01 and the initial value was the last point in the previous run. For
the 8th time period (i.e., 1 month), the value of c = 4.6726 and the initial value was
the last point in the previous run. For the 9th time period (i.e., 5 months), the value of
c = 11.6817 and the initial value was the last point in the previous run. For the 10th
time period (i.e., 11 months), the value of c = 25.6996 and the initial value was the last
point in the previous run. All parameter values are fixed in the simulation except c (see
Table 3 and Fig. 16). To determine the accuracy of model fit to data, we calculated the root
mean square error (RMSE) for the fit of FT4 and TRAb data, which is 7.3931 and 2.1257
respectively. The larger RMSE for FT4 and TRAb indicates a poor measure of accuracy
so generating patient treatment schedule might not be reliable for patient #55. The larger
Fig. 16 Two courses of MMI treatment is given for patient #55. Both FT4 and TRAb data is plotted with the
simulated solutions. The root mean square error for the fit of FT4 and TRAb data is 7.3931 and 2.1257
respectively. Blue dots indicate FT4 levels while magenta dots indicate TRAb levels in the figure
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RMSE can be due to a outlier present in patient data (see Fig. 16) and due to the lack of
TRAb data.
Results and discussions
When the treatment parameter s(t) = c = 0 and the initial concentration of MMI x0 = 0,
there is a unique steady state corresponding to hyperthyroidism, which is asymptotically
stable. After the initiation of MMI treatment, that is s(t) = c > 0 and x0 > 0, the hyper-
thyroidism steady state is moving on the monotonic decreasing function w = Nz towards
subclinical hyperthyroidism and then euthyroidism. Once patients achieve euthyrodism,
the maintenance dosage is prescribed to maintain FT4 values within the normal refer-
ence range. The value of treatment parameter c is determined in accordance with loading
or maintenance dosages, treatment time period and body volume of patients. The initial
concentration of MMI is estimated from the loading dosage of MMI.
One way to use the model is to run an experiment on clinical dosing amount and sched-
ules. For example, by keeping the dosing MMI amount constant (say 5 mg) throughout
the treatment period and varying the dosing schedule, say every 4 h for the 1st 130 days
and/or every 8 h for the 2nd 130 days.We can actually check to see if that assumption ever
results in hypothyroidism. Next, by keeping the dosing schedule constant say every day
for 360 days, we can vary the dosing amount from high doses (say 30mg) to low doses (say
5 mg) each day. After reaching the lowest dosage amount, restart the dosage amount from
high to low doses again. In this way, we can actually check to see if that assumption results
in subclinical hyperthyroidism, euthyroidism or hypothyroidism. Another way to use to
model is to find the response rate of thyroid gland to different concentrations of MMI in
the blood serum. Also, the model can be extended to account for cellular autoimmune
responses, absorption rates from the gut to serum and drug toxicity.
Conclusions
For Graves’ hyperthyroidism patients, we developed a patient-specific treatment model
to describe the time course of FT4 levels after administration of Methimazole (MMI) and
to control FT4 levels within the physiological range (7 − 18) pg/mL with an appropriate
maintenance dosage schedule. Our primary interest is to explain the natural history of
Graves’ hyperthyroidism MMI treatment, restore FT4 levels with an appropriate dosage
amount and provide a better dosage schedule through the model. The model takes the
form of a system of ordinary differential equations with four state variables, namely con-
centration ofMMI (x) at time t, concentration of free thyroxine (y) at time t, concentration
of TRAb (w) at time t and the functional size of thyroid gland (z) at time t. The model
has total of thirteen positive parameters in which we fix twelve parameters for all runs
except a treatment parameter s(t) = c. All fixed twelve parameters are determined from
patients’ data and literature (see Table 3). The treatment parameter value c varies between
patients, which in fact depends on amount ofMMI orally taken, number of days of loading
or maintenance dosages given, and body volume of the patient.
There is high variability among Graves’ hyperthyroid patients, making each patient
unique so treatment with MMI is typically challenging. Right loading, maintenance
dosage amount and schedule would help the patients control their free thyroxine lev-
els within the normal reference range over time. Our model can be used for each
patient to generate dosage amount and schedule which in turn may help prevent
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undershooting, overshooting and relapses. Basically, the model can predict when to
discontinue the treatment which helps with decision-making on the amount of oral
intake of MMI over time. With appropriate MMI dosage schedule, the clinical progres-
sion from hyperthyroidism → euthyroidism can be achieved effectively. We validated
the model with data from four Graves’ hyperthyroidism patients. To measure the qual-
ity of prediction, we have calculated root mean square error for all of these four
patients which can be cross-checked with the reference interval. The non-normalized
root mean square error interval has been obtained for FT4 and TRAb using our
patients’ data.
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